Impact of rapid multigene assays with short turnaround time (TAT) on the development of precision medicine for non-small cell lung cancer (NSCLC).

医学 克拉斯 ROS1型 肿瘤科 非小细胞肺癌 肺癌 内科学 癌症 癌症研究 结直肠癌 腺癌 A549电池
作者
Shingo Matsumoto,Takaya Ikeda,Kiyotaka Yoh,Akira K. Sugimoto,Terufumi Kato,Kei Kunimasa,Atsushi Nakamura,Ichiro Nakachi,Shoichi Kuyama,Jun Sakakibara‐Konishi,Haruko Daga,Eiji Iwama,Kageaki Taima,Naoki Furuya,Kaname Nosaki,Hiroki Izumi,Yoshitaka Zenke,Kōichi Goto
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (15_suppl): 9094-9094 被引量:3
标识
DOI:10.1200/jco.2021.39.15_suppl.9094
摘要

9094 Background: A variety of oncogene drivers have been identified in NSCLC and molecularly-stratified precision medicine has led to improved survival in advanced NSCLC. Next-generation sequencing (NGS)-based testing is utilized to detect actionable gene alterations; however, the TAT of NGS is often too long to translate into clinical decision making. Thus, rapid multi-gene testing alternatives are needed. Methods: A lung cancer genomic screening project (LC-SCRUM-Asia) capturing clinical outcome was established in 2013 to identify patients with oncogene drivers and to support the development of novel targeted therapies. Since February 2013 to May 2019 (LC-SCRUM-Asia 1st-phase), single gene testing and/or a targeted NGS assay, Oncomine Comprehensive Assay (OCA), were used for the genomic screening. Since June 2019 to December 2020 (2nd-phase), a multi-gene PCR assay (Amoy 9-in-1 test) and a rapid NGS assay (Genexus/Oncomine Precision Assay [OPA]) were also implemented as rapid multi-gene testing. Results: A total of 10667 Japanese NSCLC patients, including 6826 in the 1st-phase and 3841 in the 2nd-phase, were enrolled in the LC-SCRUM-Asia. Success rate for OCA: 93%, for 9-in-1 test: 98%, for Genexus/OPA: 96%. Median TAT for OCA: 21 days, for 9-in-1 test: 3 days, for Genexus/OPA: 4 days. The frequencies of genetic alterations detected in the 1st-/2nd-phase were EGFR: 17/24%, KRAS: 15/16%, HER2 ex20ins: 4/3%, ALK fusions: 3/3%, RET fusions: 3/2%, ROS1 fusions: 3/2%, MET ex14skip: 2/2%, BRAF V600E: 1/1%, NRG1 fusions: 0/0.2% and NTRK3 fusions: 0.05/0.04%. Overall percent agreement of 9-in-1 test compared with OCA for EGFR/KRAS/HER2/BRAF/MET/ALK/ROS1/RET/NTRK3 alterations was 98%, and that of OPA compared with OCA was 95%. The rate of patients who received targeted therapies as 1st-line treatment was significantly elevated in the 2nd-phase compared with the 1st-phase (510/3841 [13%] vs. 567/6826 [8%], p < 0.001). Through the genomic screening, 1410 (37%) and 1269 (18%) candidate patients for clinical trials of KRAS, HER2, BRAF, MET, ALK, ROS1, RET or TRK-targeted drugs were identified in the 2nd-phase and in the 1st-phase, respectively. The rate of patients who were actually enrolled into the genotype-matched clinical trials were also significantly higher in the 2nd-phase than in the 1st-phase (222 [6%] vs. 186 [3%], p < 0.001). In 1st-line treatments for advanced NSCLC patients, the median progression-free survival was 8.5 months (95% CI, 7.7−9.4) in the 2nd-phase (n = 1839) versus 6.1 months (95% CI, 5.9−6.3) in the 1st-phase (n = 4262) (p < 0.001). Conclusions: Both the 9-in-1 test and Genexus/OPA had short TATs (3−4 days), high success rates (96−98%) and good concordance (95−98%) compared with another NGS assay (OCA). These rapid multi-gene assays highly contributed to enabling precision medicine and the development of targeted therapies for advanced NSCLC.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wanci的应助被努力的扣扣酱采纳,获得10
刚刚
安静完成签到,获得积分10
刚刚
1秒前
li发布了新的文献求助10
2秒前
自然的湘完成签到,获得积分10
2秒前
秋风的应助被安静采纳,获得10
5秒前
5秒前
molihuakai的应助被安详的夜春采纳,获得10
6秒前
科研通AI6.3的应助被Liu采纳,获得30
6秒前
6秒前
6秒前
等璃子发布了新的文献求助10
7秒前
7秒前
爆米花完成签到,获得积分10
8秒前
132分vs大师完成签到,获得积分10
9秒前
披风完成签到,获得积分10
10秒前
温暖煎饼发布了新的文献求助10
10秒前
清歌发布了新的文献求助10
10秒前
11秒前
xwx发布了新的文献求助10
11秒前
脑洞疼的应助被开朗紫采纳,获得10
11秒前
12秒前
斑马完成签到,获得积分10
12秒前
111发布了新的文献求助10
13秒前
英俊的铭的应助被王诗琪采纳,获得10
14秒前
14秒前
燚槿发布了新的文献求助10
15秒前
16秒前
16秒前
等璃子完成签到,获得积分10
16秒前
業業完成签到,获得积分10
17秒前
乌龙茶发布了新的文献求助10
17秒前
19秒前
WhiteSand完成签到,获得积分10
19秒前
20秒前
ding的应助被111采纳,获得10
20秒前
水煮电吹风的应助被杨波采纳,获得10
21秒前
21秒前
22秒前
舒服的滑板完成签到 ,获得积分10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181658
求助须知:如何正确求助?哪些是违规求助? 9571454
关于积分的说明 21818081
捐赠科研通 7777987
什么是DOI,文献DOI怎么找? 3433508
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479568